Roche

Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Fierce Biotech
Genentech
Vaccibody
cancer
vaccines
Roche
cancer vaccines
Flag link:
Fourth-quarter events to watch for big pharma
Fourth-quarter events to watch for big pharma
EP Vantage
COVID-19
clinical trials
AstraZeneca
Gilead Sciences
Takeda
GSK
Roche
Alzheimer's disease
Bristol-Myers Squibb
Pfizer
Eli Lilly
Flag link:
'Rigged' healthcare? Genentech survey reveals unfair treatment among marginalized groups
'Rigged' healthcare? Genentech survey reveals unfair treatment among marginalized groups
Motley Fool
Roche
Genentech
racial diversity
racial discrimination
Flag link:
Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved
Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved
Fierce Biotech
Roche
AC Immune
Alzheimer's disease
semorinemab
Flag link:
Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer
Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer
Endpoints
Blueprint Medicines
Roche
FDA
Ayvakit
Flag link:
Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field
Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field
Fierce Biotech
Roche
M&A
Inflazome
inflammatory disease
Flag link:
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
Fierce Biotech
Roche
prostate cancer
ESMO
JNJ
Ipatasertib
Zytiga
Flag link:
ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
Fierce Pharma
ESMO
Roche
Tecentriq
triple negative breast cancer
Merck
Keytruda
Flag link:
Roche drug that previously failed in Covid-19 pneumonia shows efficacy in Phase III study
Roche drug that previously failed in Covid-19 pneumonia shows efficacy in Phase III study
MedCity News
Actemra
COVID-19
COVID-19 pneumonia
Roche
clinical trials
Flag link:
Roche’s Actemra cuts chances of COVID-19 ventilator use in phase 3 trial
Roche’s Actemra cuts chances of COVID-19 ventilator use in phase 3 trial
Pharmaforum
Roche
Actemra
clinical trials
ventilators
COVID-19
Flag link:
Roche, already prepping 2021 launch, charts big expansion plans for Lucentis eye implant
Roche, already prepping 2021 launch, charts big expansion plans for Lucentis eye implant
Fierce Pharma
Roche
macular degeneration
Lucentis
eye implants
wet age-related macular degeneration
Flag link:
Esmo 2020 preview – late-breaking immunotherapy
Esmo 2020 preview – late-breaking immunotherapy
EP Vantage
ESMO
immunotherapy
Big Pharma
Merck
Bristol-Meyers Squibb
cancer
Immunomedics
Roche
Flag link:
Sharp knives and hemophilia? No problem in Roche's new work-life miniseries
Sharp knives and hemophilia? No problem in Roche's new work-life miniseries
Fierce Pharma
hemophilia
Roche
pharma marketing
Flag link:
FDA puts Roche's Tecentriq under the lens in breast cancer after recent trial flop
FDA puts Roche's Tecentriq under the lens in breast cancer after recent trial flop
Fierce Pharma
Roche
Tecentriq
triple negative breast cancer
paclitaxel
clinical trials
FDA
Flag link:
Novartis, Roche fined $526M in France for alleged Lucentis marketing missteps
Novartis, Roche fined $526M in France for alleged Lucentis marketing missteps
Fierce Pharma
Novartis
Roche
France
Lucentis
anti-competitive scheme
Flag link:
Big pharma spinouts grow up
Big pharma spinouts grow up
EP Vantage
Big Pharma
spinoffs
Merck KGaA
Pfizer
GSK
Novartis
Roche
Sanofi
JNJ
AstraZeneca
Flag link:
Roche to launch 40M rapid coronavirus antigen tests per month, starting in Europe
Roche to launch 40M rapid coronavirus antigen tests per month, starting in Europe
Fierce Biotech
Roche
COVID-19
diagnostics
Europe
FDA
Emergency Use Authorization
Flag link:
AbbVie keeps TV ad lead in July, Roche and Pfizer follow in mildly curbed pharma TV market
AbbVie keeps TV ad lead in July, Roche and Pfizer follow in mildly curbed pharma TV market
Fierce Pharma
television ads
Roche
Pfizer
AbbVie
pandemic
DTC ads
COVID-19
Flag link:
Is valrox dead?
Is valrox dead?
EP Vantage
Biomarin
hemophilia A
valrox
gene therapy
Roche
Pfizer
FDA
Flag link:
Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?
Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?
Endpoints
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
clinical trials
Pfizer
Roche
Flag link:

Pages